SOURCE: 3BL Media, LLC
Bayer will buy Teva Pharmaceutical, a U.S.-animal health business for $145 million. The acquisition reinforces the food animal franchise of Bayer Healthcare by providing a range of anti-infective solutions for livestock. It will also expand the company’s portfolio with dermatological, pet wellness, and nutraceutical products.
Abbott is expanding product labeling for its ALK test, a companion diagnostic test to help identify patients for lung cancer. The new labeling will allow the test to be marketed in the European Union. The ALK test offers clinicians a standardized, clinically validated method to identify patients most likely to benefit from new therapies. Abbott’s test was the only diagnostic test used in multi-center global clinical trials in conjunction with a Pfizer drug to allow physicians to make treatment decisions.
For more information on these and other stories, go to 3blmedia.com
KEYWORDS: Bayer, Teva Pharmaceutical, animal, Abbott, Cancer, European Union, Pfizer, 3bl Media, Health, Health Minute
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here